Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beyond Air, Inc.XAIR · Entity 8379 | Chief Medical Officer | December 27, 2023 | December 29, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beyond Air, Inc.
Report date December 27, 2023 · Filed December 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,577 |
Reported balance
After 2023-12-27 transaction · row 1
1 source rowRow 1 · 2023-12-27 · Sale · Disposed 3,423 · Balance 46,577 F1: The sales reported on this Form 4 represent shares of common stock of Beyond Air, Inc. sold by the reporting person to cover tax withholding obligations in connection with the vesting of previously granted restricted stock units. F2: This price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.15 to $2.34, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 represent shares of common stock of Beyond Air, Inc. sold by the reporting person to cover tax withholding obligations in connection with the vesting of previously granted restricted stock units.
F2: This price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.15 to $2.34, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2023 Filed Dec 29, 2023 21:15 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 3,423 | $2.21 | $7,578.52 |
DisclosureSEC source: 0001493152-23-046580 · ownership.xml · nonDerivative · entry 1 Myers Jeff Lynn · CIK 0001971112 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,577 F1 · kind: The sales reported on this Form 4 represent shares of common stock of Beyond Air, Inc. sold by the reporting person to cover tax withholding obligations in connection with the vesting of previously granted restricted stock units. F2 · price: This price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.15 to $2.34, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| March 27, 2023 Filed Mar 28, 2023 20:36 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001493152-23-009295 · ownership.xml · derivative · entry 2 Myers Jeff Lynn · CIK 0001971112 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-03-26 F2 · derivative.exercise_date: The option will vest as to 25% of the shares of common stock underlying the option on March 27, 2024, with the remainder vesting in equal annual installments on March 27 of each of the three ensuing years thereafter until vested in full, in each case subject to the reporting person's continued service with the Issuer. Read SEC document |
| March 27, 2023 Filed Mar 28, 2023 20:36 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-009295 · ownership.xml · nonDerivative · entry 1 Myers Jeff Lynn · CIK 0001971112 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Represents restricted stock units ("RSUs") granted on March 27, 2023 to acquire 50,000 shares of common stock of Beyond Air, Inc. (the "Issuer"). The RSUs will vest as to 20% of the shares of common stock underlying the RSUs on December 15, 2023, with the remainder vesting in equal annual installments on December 15 of each of the four ensuing years thereafter until vested in full, in each case subject to the reporting person's continued service with the Issuer. Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.